Molecular targeted therapy for leukemic stem cells

Research output: Contribution to journalReview article

Abstract

Acute myelogenous leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), an ultimate therapeutic target for AML. LSCs play a central role in the propagation of leukemia through their unique stem cell like properties, and LSCs share the many functional molecules with their normal counterpart hematopoietic stem cells (HSCs). For the establishment of LSCs-specific therapeutic approaches, it is quite important to understand the biological differences between LSCs and HSCs. Recent, studies have succeeded in clarifying these biological differences. In this review, I would like to introduce the biological significance of LSCs and discuss the molecular targeted therapy against LSCs.

Original languageEnglish
Pages (from-to)811-815
Number of pages5
JournalNihon rinsho. Japanese journal of clinical medicine
Volume73
Issue number5
Publication statusPublished - May 1 2015

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'Molecular targeted therapy for leukemic stem cells'. Together they form a unique fingerprint.

  • Cite this